Hiperparatiroidismo secundarioActualización y revisión bibliográfica

  1. Alcaide Lucena M. 1
  2. Hernández García E. 1
  3. Reyes Lartartegui S. 1
  4. Gallart Aragón T. 1
  5. García Rubio J. 1
  6. Sánchez Barrón M. T. 1
  7. Torné Poyatos P. 1
  1. 1 Hospital Universitario San Cecilio. Granada.
Revista:
Cirugía Andaluza

ISSN: 2695-3811,  1130-3212

Año de publicación: 2020

Volumen: 31

Número: 3

Páginas: 294-299

Tipo: Artículo

DOI: 10.37351/2020313.11 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: Cirugía Andaluza

Resumen

El hiperparatiroidismo secundario es una complicación frecuente en la enfermedad renal crónica (ERC). La indicación quirúrgica ha disminuido de forma considerable debido a los recientes avances en el tratamiento médico dirigido tanto por la mejora de los fármacos orales ya conocidos, como por la introducción de fármacos intravenosos que, además de aumentar su efectividad, contribuyen a la adherencia terapéutica administrándolos en el hospital asociados a terapia renal sustitutiva. En pacientes refractarios al tratamiento médico, la paratiroidectomía continúa siendo una herramienta adecuada. Con el presente artículo realizamos una revisión en el tratamiento médico, así como de las indicaciones quirúrgicas actuales.

Referencias bibliográficas

  • Prados M, Bover J, González M, Hervás J, Ocharan J, Foraster A et al. Guía de práctica clínica de la Sociedad Española de Diálisis y Trasplante de las alteraciones del metabolismo mineral y óseo de la enfermedad renal crónica (CKD-MBD). Diálisis y Trasplante 2011; 32(3):108-118.
  • Phelps K. Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism. Nutrients 2017; 9(5):427.
  • Cordellat I. Hiperparatiroidismo: ¿primario o secundario?. Reumatología Clínica, 8(5), pp.287-291.
  • Goodman WG, Quarles LD. Development and progressión of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74: 276-88
  • Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010;77: 292–8
  • Onal M, Carlson A, Thostenson J, Benkusky N, Meyer M, Lee S et al. A Novel Distal Enhancer Mediates Inflammation-, PTH-, and Early Onset Murine Kidney Disease-Induced Expression of the Mouse Fgf23 Gene. JBMR Plus 2017;2(1):31-46
  • KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder. Kidney Int Suppl. 2017; 7: 1–59
  • Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008;12:514–25
  • Cordellat I. Hiperparatiroidismo: ¿primario o secundario?. Reuma Clínic 2012;8(5):287-291.
  • Miller P. Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep 2014;3: 542.
  • Bellasi A, Ferramosca E, Muntner P, Ratti C, Wildman RP, Block GA, et al. Correlation of simple imaging test and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int. 2006;70:1623—8
  • Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. American Journal of Physiology-Renal Physiology 2010;299(4):F882-F889.
  • Spasovski G. Bone Biopsy as a Diagnostic Tool in the Assessment of Renal Osteodystrophy. The International Journal of Artificial Organs 2004;27(11):918-923.
  • Galassi A, Ciceri P, Fasulo E, Carugo S, Cianciolo G, Cozzolino M. Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly. Drugs Aging. 2019;36(10):885-895.
  • Chazot C, Fadel B, Kareche M, Puyoo O, Jean G. Short-term effects with sucroferric oxyhydroxide in hemodialysis patients: Experience in NephroCare France. Nephrol Ther. 2019; 10.
  • Susantitaphong P, Vadcharavivad S, Susomboon T. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Ren Fail. 2019;41(1):326-333.
  • Shireman TI, Almehmi A, Wetmore JB, Lu J, Pregenzer M, Quarles LD. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis. 2010;56(6):1108-1116.
  • Cozzolino M, Galassi A, Conte F, Mangano M, Di Lullo L, Bellasi A. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. Ther Clin Risk Manag. 2017; 1, 13: 679-689.
  • Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, et al. EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012; 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624.
  • Tominaga Y, Numano M, Tanaka Y. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:87–96.
  • Jain N, Reilly R. Hungry bone syndrome. Current Opinion in Nephrology and Hypertension 2017;26(4):250-255.
  • Lau WL, Obi Y, Kalantar-Zadeh K. Paratiroidectomía en el manejo del hiperparatiroidismo secundario. Clin J Am Soc Nephrol . 2018; 13 (6): 952-961. doi: 10.2215 / CJN.10390917
  • Schneider R, Slater E, Karakas E, Bartsch D, Schlosser K. Initial Parathyroid Surgery in 606 Patients with Renal Hyperparathyroidism. World Journal of Surgery 2011;36(2):318-326.
  • Tominaga Y, Kakuta T, Yasunaga C. Evaluation of parathyroidectomy for secondary and tertiary hyperparathyroidism by the Parathyroid Surgeons’ Society of Japan. Ther Apher Dial. 2016;20:6–11.
  • Wang T. Is There an Optimal Time for Parathyroidectomy in Patients with Secondary Hyperparathyroidism?. World Journal of Surgery 2019;43(8), pp.1989-1990.
  • He Q, Zhuang D, Zheng L, Fan Z, Zhou P, Zhu J et al. Total parathyroidectomy with trace amounts of parathyroid tissue autotransplantation as the treatment of choice for secondary hyperparathyroidism: a single-center experience. BMC Surgery 2014;14(1):26
  • Gong L, Tang W, Lu J, Xu W. Thermal ablation versus parathyroidectomy for secondary hyperparathyroidism: A meta-analysis. International Journal of Surgery 2019;70:13-18.
  • Chen L. Feasibility and efficacy in ultrasound guided percutaneous microwave ablation of primary hyperparathyrodism with parathyroid nodules. Endocrine Abstracts. 2018.
Fuente de los datos: Dialnet